REFERENCES
- Li W-Y, Chong S SN, Huang E Y, Tuan T-L. Plasminogen activator/plasmin system: a major player in wound healing?. Wound Repair Regen 2003; 11: 239–247, [PUBMED], [INFOTRIEVE], [CSA]
- Berta A, Tozser J, Holley F J. Determination of plasminogen activator activities in normal and pathological human tears. The significance of tear plasminogen activators in the inflammatory and traumatic lesions of the cornea and the conjunctiva. Acta Ophthalmol. 1990; 68: 508–514, [CSA]
- Twining S S, Wilson P M, Ngamkitidechakul C. Extrahepatic synthesis of plasminogen in the human cornea is up-regulated by interleukins-1α and -1β. Biochem J. 1999; 339: 705–712, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Twining S S, Schulte D P, Zhou X, et al. Changes in rat corneal matrix metalloproteinases and serine proteinases under vitamin A deficiency. Curr Eye Res. 1997; 16: 158–165, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Tao Y, Bazan H E, Bazan N G. Platelet-activating factor enhances urokinase-type plasminogen activator gene expression in corneal epithelium. Invest Ophthalmol Vis Sci. 1996; 37: 2037–2046, [PUBMED], [INFOTRIEVE], [CSA]
- Ramsby M L, Kreutzer D L. Fibrin induction of tissue plasminogen activator expression in corneal endothelial cells in vitro. Invest Ophthalmol Vis Sci. 1993; 34: 3207–3219, [PUBMED], [INFOTRIEVE], [CSA]
- Wang Z, Kurpakus-Wheater M. Decreased plasminogen activator inhibitor-1 secretion in hypoxic corneal epithelial cells is associated with increased urokinase plasminogen activator activity. Int J Biochem Cell Biol. 2003; 35: 339–348, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Berman M. The pathogenesis of corneal epithelial defects. Acta Ophthalmol Suppl. 1989; 192: 55–64, [PUBMED], [INFOTRIEVE], [CSA]
- Berman M, Leary R, Gage J. Evidence for a role of the plasminogen activator-plasmin system in corneal ulceration. Invest Ophthalmol Vis Sci. 1980; 19: 1204–1221, [PUBMED], [INFOTRIEVE], [CSA]
- Kao W W, Kao C W, Kaufman A H, et al. Healing of corneal epithelial defects in plasminogen- and fibrinogen-deficient mice. Invest Ophthalmol Vis Sci. 1998; 39: 502–508, [PUBMED], [INFOTRIEVE], [CSA]
- Drew A F, Schiman H L, Kombrinck K W, et al. Persistent corneal haze after excimer laser photokeratectomy in plasminogen-deficient mice. Invest Ophthalmol Vis Sci. 2000; 41: 67–72, [PUBMED], [INFOTRIEVE], [CSA]
- Watanabe M, Yano W, Kondo S, et al. Up-regulation of urokinase-type plasminogen activator in corneal epithelial cells induced by wounding. Invest Ophthalmol Vis Sci. 2003; 44: 3332–3338, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Morimoto K, Mishima H, Nishida T, Otori T. Role of urokinase type plasminogen activator (u-PA) in corneal epithelial migration. Thromb Haemost. 1993; 69: 387–391, [PUBMED], [INFOTRIEVE], [CSA]
- Tozser J, Berta A. Plasminogen activator inhibitors in human tears. Acta Ophthalmol. 1991; 69: 426–431, [CSA]
- Williams D L, Risse B, Kim S, Saunders D, et al. Plasminogen activator inhibitor type 2 in human corneal epithelium. Invest Ophthalmol Vis Sci. 1999; 40: 1669–1675, [PUBMED], [INFOTRIEVE], [CSA]
- Tervo T, Tervo K, van Setten G B, et al. Plasminogen activator and its inhibitor in the experimental corneal wound. Exp Eye Res. 1989; 48: 445–449, [PUBMED], [INFOTRIEVE], [CSA]
- Sawaguchi S, Twining S S, Yue B Y, et al. α 2-Macroglobulin levels in normal human and keratoconus corneas. Invest Ophthalmol Vis Sci. 1994; 35: 4008–4014, [PUBMED], [INFOTRIEVE], [CSA]
- Twining S S, Fukuchi T, Yue B Y, et al. Corneal synthesis of α 1-proteinase inhibitor (α 1-antitrypsin). Invest Ophthalmol Vis Sci. 1994; 35: 458–462, [PUBMED], [INFOTRIEVE], [CSA]
- Kolev K, Lerant I, Tenekejiev K, Machovich R. Regulation of fibrinolytic activity of neutrophil leukocyte elastase, plasmin, and miniplasmin by plasma protease inhibitors. J Biol Chem. 1994; 269: 17030–17034, [PUBMED], [INFOTRIEVE], [CSA]
- Gettins P GW. Serpin structure, mechanism and function. Chem Rev. 2002; 102: 4751–4804, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Frank P S, Douglas J T, Locher M, et al. Structural/functional characterization of the α 2-plasmin inhibitor C-terminal peptide. Biochemistry. 2003; 42: 1078–1085, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Bangert K, Johnsen A H, Christensen U, Thorsen S. Different N-terminal forms of alpha 2-plasmin inhibitor in human plasma. Biochem J. 1993; 291: 623–625, [PUBMED], [INFOTRIEVE], [CSA]
- Twining S S, Fukuchi T, Yue B YJT, et al. α 2-Macroglobulin, is present in and synthesized by the cornea. Invest Ophthalmol Vis Sci. 1994; 35: 3226–3233, [PUBMED], [INFOTRIEVE], [CSA]
- Twining S S, Everse S J, Wilson P M, et al. Localization and quantification of α -1-proteinase inhibitor in the human cornea. Curr Eye Res. 1989; 8: 389–395, [PUBMED], [INFOTRIEVE], [CSA]
- Lowry O H, Rosebrough N J, Farr A L, Randall R J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951; 193: 265–275, [PUBMED], [INFOTRIEVE], [CSA]
- Cesarone C F, Bolognesi C, Santi L. Improved microfluorometric DNA determination in biological material using 33258 Hoechst. Anal Biochem. 1979; 100: 188–197, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Griffith M, Osborne R, Munger R, et al. Functional human corneal equivalents constructed from cell lines. Science. 1999; 286: 2169–2172, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Watsky M A, Griffith M, Wang D-A, Tigyi G J. Phospholipid growth factors and corneal wound healing. Ann NY Acad Sci. 2000; 905: 142–158, [PUBMED], [INFOTRIEVE], [CSA]
- Ngamkitidechakul C, Warejcka D J, Burke J M, O'Brien W J, Twining S S. Sufficiency of the reactive site loop of maspin for induction of cell-matrix adhesion and inhibition of cell invasion: conversion of ovalbumin to a maspin-like molecule. J Biol Chem. 2003; 278: 31796–31806, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Twining S S, Fukuchi T, Yue B YJT, et al. α 1-Antichymotrypsin is present in and synthesized by the cornea. Curr Eye Res. 1994; 13: 433–439, [PUBMED], [INFOTRIEVE], [CSA]
- Lee K N, Lee C S, Tae W-C, et al. Cross-linking of wild-type and mutant α 2-antiplasmins to fibrin by activated factor XIII and by a tissue transglutaminase. J Biol Chem. 2000; 275: 37382–37389, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Saito H, Goldsmith G H, Moroi M, Aoki N. Inhibitory spectrum of α 2-plasmin inhibitor. Proc Natl Acad Sci USA. 1979; 76: 2013–2017, [PUBMED], [INFOTRIEVE], [CSA]
- Rijken D C, Juhan-Vague I, Collen D. Complexes between tissue-type plasminogen activator and proteinase inhibitors in human plasma, identified with an immunoradiometric assay. J Lab Clin Med. 1983; 101: 285–294, [PUBMED], [INFOTRIEVE], [CSA]
- Le D M, Besson A, Fogg D K, et al. Exploitation of astrocytes by glioma cells to facilitate invasiveness: a mechanism involving matrix metalloproteinase-2 and the urokinase-type plasminogen activator-plasmin cascade. J Neurosci. 2003; 23: 4034–4043, [PUBMED], [INFOTRIEVE], [CSA]
- Monea S, Lehti K, Keski-Oja J, Mignatti P. Plasmin activates pro-matrix metalloproteinase-2 with a membrane-type 1 matrix metalloproteinase-dependent mechanism. J Cell Physiol. 2002; 192: 160–170, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Davis G E, Pintar A KA, Salazar R, Maxwell S A. Matrix metalloproteinase-1 and -9 activation by plasmin regulates a novel endothelial cell-mediated mechanism of collagen gel contraction and capillary tube regression in three-dimensional collagen matrices. J Cell Sci. 2001; 114: 917–930, [PUBMED], [INFOTRIEVE], [CSA]
- Andreasen P, Kjoller L, Christensen L, Duffy M J. The urokinase-type plasminogen activator system in cancer metastasis. Int J Cancer. 1997; 72: 1–22, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Krishnan S, Deora A B, Annes J P, et al. Annexin II-mediated plasmin generation activates TGF-β 3 during epithelial-mesenchymal transformation in the developing avian heart. Dev Biol. 2004; 265: 140–154, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Matsuno H, Kozawa O, Yoshimi N, et al. Lack of alpha2-antiplasmin promotes pulmonary heart failure via overrelease of VEGF after acute myocardial infarction. Blood. 2002; 100: 2487–2493, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Salonen E M, Tervo T, Torma E, et al. Plasmin in tear fluid of patients with corneal ulcers: basis for new therapy. Acta Ophthalmol. 1987; 65: 3–12, [CSA]
- Virtanen T, Honkanen N, Harkonen M, et al. Elevation of tear fluid plasmin activity of contact lens wearers studied with a rapid fluorometric assay. Cornea. 1994; 13: 210–213, [PUBMED], [INFOTRIEVE], [CSA]
- Cejkova J, Lojda Z, Vacik J, et al. Histochemical changes in the rabbit cornea and plasmin activity in the tear fluid during contact lens wear. Favourable influence of protease inhibitors (aprotinin, PC5, elastatinal). Histochemistry. 1992; 97: 69–76, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]